NCT01900782View on ClinicalTrials.gov

Efficacy and Safety Study of Subcutaneous Secukinumab in Treatment of Subjects With Moderate to Severe Chronic Plaque-type Psoriasis as Compared to Etanercept and Placebo.

PHASE3WithdrawnINTERVENTIONAL
0
Timeline

Start Date

October 31, 2013

Primary Completion Date

June 30, 2015

Study Completion Date

June 30, 2015

Conditions
Psoriasis
Interventions
BIOLOGICAL

Intervention A

Prefilled syringe.

BIOLOGICAL

Intervention B

Prefilled syringe.

BIOLOGICAL

Placebo

Prefilled syringe to match experimental drug and active comparator.

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY